Literature DB >> 18552243

Optimum electrolyte composition of a dialysis solution.

Bengt Rippe1, Daniele Venturoli.   

Abstract

In patients undergoing peritoneal dialysis (PD) for end-stage renal failure, the optimum electrolyte composition of a dialysis solution is that which best serves the homeostatic needs of the body. Comparing the transperitoneal removal of electrolytes by conventional PD solutions (CPDSs) with that by normal kidneys, it is evident that peritoneal removal is in the lower range of what can be considered "normal." Given the electrolyte composition of CPDSs and a total dwell volume of 4 exchanges of 2 L each, approximately 90 mmol NaCl, 40 mmol K(+), 10 - 15 mmol HPO(4)(-) and 1 - 2 mmol Ca(2+) can be removed daily [plus 1 L ultrafiltration (UF)]. Na(+), Ca(2+), and Mg(2+) are supplied in CPDSs in concentrations close to their plasma concentrations, which makes their removal almost entirely dependent on UF. In UF failure (UFF), plasma levels of the foregoing ions will tend to rise, producing a higher diffusion gradient to compensate for their defective UF removal. Peritoneal removal of HCO(3)(-), HPO(4)(-), and K(+) are usually quite efficient because of the zero CPDS concentrations of these ions. Approximately 150 mmol HCO(3)(-) is lost daily with CPDSs, compensated for by the addition of 30 - 40 mmol/L lactate, or, with the use of multi-compartment bags, bicarbonate instead. However, a mixture of bicarbonate and lactate should be preferred as a buffer, to avoid intracellular acidosis from high levels of pCO(2) in the dialysis fluid. For patients on continuous ambulatory peritoneal dialysis (CAPD) without UFF and with some residual renal function, PD fluid concentrations of Na(+) 130 - 133 mmol/L, Ca(2+) 1.25 - 1.35 mmol/L, and Mg(2+) 0.25 - 0.3 mmol/L seem appropriate. With reduced UF after a few years of PD, the removal of fluid and electrolytes often becomes deficient. Dietary salt restriction can be prescribed, but it is hard to implement. The use of low-Na(+) solution (LNa) is a potential alternative. The reduction in osmolality resulting from Na(+) removal in LNa should preferably be compensated by the addition of glucose (G). In a recent study, a regimen including 1 LNa exchange daily (Na(+) 115 mmol/L) in a G-compensated solution showed very promising effects on blood pressure and fluid status. However, large-scale randomized controlled studies have to be performed to definitively settle the role of LNa in volume-overloaded patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18552243

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  5 in total

1.  Peritoneal dialysis in infants: never lose sight of-and from-arterial hypotension!

Authors:  Franz Schaefer
Journal:  Perit Dial Int       Date:  2015 Mar-Apr       Impact factor: 1.756

2.  End-stage kidney disease in infancy: an educational review.

Authors:  Keia R Sanderson; Bradley A Warady
Journal:  Pediatr Nephrol       Date:  2018-11-21       Impact factor: 3.714

3.  Peritoneal dialysis tailored to pediatric needs.

Authors:  C P Schmitt; A Zaloszyc; B Schaefer; M Fischbach
Journal:  Int J Nephrol       Date:  2011-06-08

4.  Magnesium in chronic kidney disease Stages 3 and 4 and in dialysis patients.

Authors:  John Cunningham; Mariano Rodríguez; Piergiorgio Messa
Journal:  Clin Kidney J       Date:  2012-02

5.  Severe neurological outcomes after very early bilateral nephrectomies in patients with autosomal recessive polycystic kidney disease (ARPKD).

Authors:  Kathrin Burgmaier; Gema Ariceta; Martin Bald; Anja Katrin Buescher; Mathias Burgmaier; Florian Erger; Michaela Gessner; Ibrahim Gokce; Jens König; Claudia Kowalewska; Laura Massella; Antonio Mastrangelo; Djalila Mekahli; Lars Pape; Ludwig Patzer; Alexandra Potemkina; Gesa Schalk; Raphael Schild; Rukshana Shroff; Maria Szczepanska; Katarzyna Taranta-Janusz; Marcin Tkaczyk; Lutz Thorsten Weber; Elke Wühl; Donald Wurm; Simone Wygoda; Ilona Zagozdzon; Jörg Dötsch; Jun Oh; Franz Schaefer; Max Christoph Liebau
Journal:  Sci Rep       Date:  2020-09-29       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.